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elomeres, found at eukaryotic 
chromosome ends, are made up 
of tandem DNA repeats. In most 
cells, the number of telomeric repeats is 
reduced with each cell division. If telom-
eres are ever completely lost, the exposed 
chromosome ends are recognized as 
damaged DNA, activating a DNA dam-
age response that can eventually lead to 
senescence or apoptosis. The rare cell 
that escapes these fates risks developing 
chromosomal aberrations or genomic in-
stability and becoming cancerous (1).
The contribution that telomeres and 
telomerase—the enzyme that maintains 
telomere length in cells—make to pre-
venting cancer (2) and aging (3–5) is the 
research passion of Dr. María Blasco at 
the Spanish National Cancer Research 
Center (CNIO) in Madrid. She entered 
the telomerase fi  eld just as it was taking 
off, as a postdoc in Carol Greider’s labo-
ratory at the Cold Spring Harbor Labora-
tory in New York (1). Her career took off 
as well, and her work has been at the 
leading edge of the fi  eld ever since. We 
caught up with her at her offi  ce to learn 
more about her work on the cell’s inter-
nal countdown clock.
PRE-LAUNCH HOLD
What attracted you to studying 
telomere biology?
I think I always had a love for science 
generally, even as a child. I had a chemis-
try set growing up, and I 
loved to play with it. When I 
was in University, the topics 
that interested me most were 
cancer and aging. But I 
didn’t get to work on these 
subjects right away because 
when I was looking for a 
laboratory for my PhD I felt 
the best laboratory at my in-
stitution was Margarita 
Salas’ laboratory. She worked on the bac-
teriophage DNA polymerase Phi29 and 
on the end-replication problem, which 
concerns how you copy DNA at the very 
end of a linear strand. While I wasn’t ini-
tially interested in that topic, I knew I 
would learn a lot of useful techniques in 
her laboratory, like molecular biology. 
And I was right—those skills were very 
helpful when I got to Carol Greider’s lab-
oratory for my postdoc.
Carol was just starting a junior group 
at Cold Spring Harbor, and I was happy 
to have the opportunity to work with her 
because a link between telomeres, can-
cer, and aging was hypothesized, but it 
had not yet been proven. The genes that 
make up the mammalian telomerase had 
not yet been identifi  ed, so there was a lot 
of room for discovery in the fi  eld. My 
project was to try to isolate one of the 
telomerase genes and then make a knock-
out mouse lacking telomerase activity. 
That part of the project was a big change 
for me because I’d never worked with 
mice before. I had to take a course on 
mouse embryology.
Was being in Cold Spring Harbor—in a 
different country—a big change for 
you, as well?
Professionally, yes it was. Most of the 
people there were postdocs, and it was 
a competitive environment—everyone 
wanted to succeed, to get a job as an in-
dependent researcher somewhere. You 
had the feeling that you were in a place 
that was making a big impact, where you 
could learn many things, 
and that, if you were suc-
cessful, it would help you 
in the rest of your career.
What things did you learn 
there that you think have 
served you best?
I think an important thing I 
learned is that European 
scientists lack a little bit of 
the self-confi  dence that American scien-
tists have. Americans have a different atti-
tude toward science and toward their ca-
reers; they set their goals much higher. 
And I think that’s important. You need to 
have the confi  dence to ask vital questions.
COUNTDOWN
Did you consider staying in the United 
States after your postdoctoral studies?
I had always planned on coming back to 
Spain. I had some job offers in the US, but 
in the end I got a very good position in 
Madrid, so I decided to start my inde-
pendent career there.
I got a civil service position at the 
Spanish National Biotechnology Center. 
For a position like that, you take an exam, 
and if you pass then you can be hired by 
the government as a civil servant. The 
good thing about that is that you have a 
permanent, indefi  nite contract—you don’t 
have to worry about anybody fi  ring you. 
My department had plenty of money, so I 
had a lot of space, the ability to hire peo-
ple, and so on. It was very easy to get a lot 
done in a short time.
I did enjoy my time in the States, and 
of course I go back every few years for 
meetings and so on, and I hope I will 
someday get to go back for a sabbatical. 
But I think it was a good decision to re-























Blasco is at the forefront of research on the function of telomeres in 
cancer and aging.
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wanted to do, and I also wanted to give 
back to my country. Spain isn’t a very 
well-known country for research, so I 
think it’s good when Spanish scientists 
who go abroad come back and help bring 
science in Spain to a higher level.
And now you’re the director of the 
molecular oncology program at CNIO?
Yes. I was recruited here by the director of 
CNIO, when they were just building the 
center. In the context of Spanish science, 
CNIO is really a center of excellence. It 
runs on a different model than the civil 
servant system; it’s more similar to the 
American model of a research institute.
Have telomeres and telomerase 
remained the major focus of your 
laboratory?
My laboratory has always focused on 
trying to understand the role of telomeres 
and telomerase in cancer and aging. Our 
main tools in our work have been various 
mouse models. First we studied a telom-
erase-defi  cient mouse, which showed us 
both that telomere loss can cause aging 
and also that telomeres act primarily as a 
tumor-suppressing mechanism. In other 
studies we showed that short telomeres 
could interfere with the normal repair of 
lesions in the genome. We also generated 
telomerase-overexpressing mice, through 
which we demonstrated one of the most 
signifi   cant contributions my laboratory 
has made: that increasing telomerase ex-
pression extends the lifespan of mice. 
That was really the fi  rst time it was shown 
that telomerase has anti-aging activity in 
a mammal. And, of 
course, we have also been 
using mice to try to un-
derstand the role of tel-
omerase in cancer.
TAKE-OFF
Why does telomere loss 
cause aging?
It’s well known now that, 
as cells age, their telomer-
es become shorter and 
shorter. If you delay this 
telomere shortening, you 
can delay aging. On the 
other hand, if you accelerate telomere 
shortening, you can accelerate 
aging. This is particularly rele-
vant at the level of the stem cell 
because stem cells with dys-
functional telomeres are not 
able to mobilize into tissues. 
It’s because of this impact on 
stem cells that we think telom-
eres affect aging, and this is 
something we’re studying quite 
a lot in the laboratory.
More recently we have also 
been studying telomeres in induced pluri-
potent stem cells. Induced pluripotency is 
a technology that allows you to convert a 
differentiated cell back into an embryonic 
stem cell–like state. It’s very interesting 
for us because we found out that, during 
this conversion process, telomeres are re-
juvenated. It would be interesting to fi  nd 
out which factors are important for this 
rejuvenation of the telomeres because 
they could be important targets in cancer 
and aging.
Have you also been 
working on other 
components of the 
telomere maintenance 
machinery?
Yes. We started by being 
interested in DNA repair 
proteins that are also 
bound to telomeres—Ku 
and DNA-Pk, for exam-
ple—and later we became 
interested in activities that 
are important for the epigenetic regula-
tion of telomere length. More recently we 
have been interested in understanding the 
role of telomere-binding proteins called 
shelterins. There are six shelterins, and 
we’ve developed both loss-of-function 
and gain-of-function mouse models to 
explore the role of shelterins in cancer 
and aging.
What’s the project you’re most excited 
about at the moment?
I think one of the things that we are most 
excited about right now is the anti-aging 
activity of telomerase. We’re still explor-
ing that and trying to come closer to a real 
therapy where you could 
use telomerase activa-
tion as a way to rejuve-
nate tissues. We’re also 
very excited about using 
induced pluripotency to 
identify factors that are 
important for regulating 
telomere length.
I’m excited about the 
directions we’re taking 
now. Ours is a competi-
tive fi  eld, so it’s important to think about 
trying things that others are not doing. 
Your work has to be both original and rel-
evant to the fi  eld.
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Mice overexpressing telomerase (TERT) age more slowly than 
normal mice.
I
M
A
G
E
 
C
O
U
R
T
E
S
Y
 
O
F
 
T
H
E
 
B
L
A
S
C
O
 
L
A
B
O
R
A
T
O
R
Y